One in three women with a HER2‐positive pure DCIS lesion develops a subsequent HER2‐negative invasive breast cancer (Visser et al., 2019), although the clonal relationship between primary and recurrent lesions was not investigated in that study. Here, ERBB2 is linked to invasive breast carcinoma.